Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
grade A 5.51 -8.47% -0.51
ADVM closed down 8.47 percent on Friday, March 22, 2019, on 3.35 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical ADVM trend table...

Date Alert Name Type % Chg
Mar 22 Slingshot Bullish Bullish Swing Setup 0.00%
Mar 22 Volume Surge Other 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Pocket Pivot Bullish Swing Setup -8.47%
Mar 21 Upper Bollinger Band Walk Strength -8.47%
Mar 21 Wide Bands Range Expansion -8.47%
Mar 21 Overbought Stochastic Strength -8.47%
Mar 21 Up 3 Days in a Row Strength -8.47%
Mar 21 Up 4 Days in a Row Strength -8.47%

Older signals for ADVM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Disease Gene Therapy Macular Degeneration Wet Age Related Macular Degeneration Gene Therapy Products Adverum Biotechnologies Rare Genetic Disease Retinoschisis
Is ADVM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.72
52 Week Low 2.62
Average Volume 402,198
200-Day Moving Average 4.6797
50-Day Moving Average 3.9876
20-Day Moving Average 4.924
10-Day Moving Average 5.401
Average True Range 0.3951
ADX 70.9
+DI 33.9867
-DI 10.2922
Chandelier Exit (Long, 3 ATRs ) 5.0347
Chandelier Exit (Short, 3 ATRs ) 4.7053
Upper Bollinger Band 6.1011
Lower Bollinger Band 3.7469
Percent B (%b) 0.75
BandWidth 47.810723
MACD Line 0.5254
MACD Signal Line 0.459
MACD Histogram 0.0664
Fundamentals Value
Market Cap 238.51 Million
Num Shares 43.3 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -3.63
Price-to-Sales 75.42
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.61
Resistance 3 (R3) 6.64 6.32 6.42
Resistance 2 (R2) 6.32 6.04 6.30 6.36
Resistance 1 (R1) 5.91 5.87 5.75 5.88 6.30
Pivot Point 5.59 5.59 5.51 5.57 5.59
Support 1 (S1) 5.18 5.31 5.02 5.15 4.72
Support 2 (S2) 4.86 5.14 4.84 4.66
Support 3 (S3) 4.45 4.86 4.60
Support 4 (S4) 4.42